See analyst estimates and all valuation multiples for Nutraceuticals & Cosmeceuticals
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $25.4B | 1.6x | 6.9x | |
| $20.1B | 17.8x | 55.6x | |
| $17.0B | 11.0x | 33.3x | |
| $9.4B | 3.0x | 7.3x | |
| $7.2B | 9.5x | 35.6x | |
| $6.8B | 4.4x | 22.6x | |
| $4.1B | 2.0x | 13.3x | |
| $3.6B | n/a | n/a | |
| $3.1B | 2.3x | 8.7x | |
| $3.1B | 10.3x | 25.5x | |
| $3.0B | 1.4x | 8.2x | |
| $2.3B | 7.8x | 15.5x | |
| $1.6B | 6.8x | 26.5x | |
| $1.6B | n/a | n/a | |
| $1.3B | 1.1x | 4.5x | |
| $1.3B | 2.3x | 11.7x | |
| $1.1B | 8.2x | 30.7x | |
| $1.1B | n/a | n/a | |
| $1.0B | n/a | n/a | |
| $905M | 6.0x | 17.9x | |
| $876M | 3.5x | 9.1x | |
| $667M | n/a | n/a | |
| $560M | 1.2x | 5.9x | |
| $541M | n/a | n/a | |
| $539M | 10.9x | 30.6x | |
| $531M | 3.9x | 14.5x | |
| $240M | 3.5x | n/a | |
| $144M | 2.2x | 10.0x | |
| $101M | n/a | n/a | |
| $33.2M | n/a | n/a | |
| $22.0M | 0.9x | -257.5x | |
| $15.8M | n/a | n/a | |
| $15.0M | n/a | n/a | |
| $14.5M | 7.5x | -1.3x | |
| $7.5M | n/a | n/a | |
| $4.1M | n/a | n/a | |
| $2.0M | n/a | n/a | |
| -$3.5M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Nutraceuticals & Cosmeceuticals